Clinical biotech firm Alector Q3 revenue beats expectations

Reuters

Nov 07

Clinical biotech firm Alector Q3 revenue beats expectations

Overview

Alector Q3 2025 revenue beats analyst expectations despite a year-over-year decline
Net loss for Q3 2025 narrows compared to the same period last year
Company implements 47% workforce reduction to focus on high-priority programs

Outlook

Company anticipates collaboration revenue between $13 mln and $18 mln for 2025
Alector targets IND filing for AL137 in 2026
Independent interim analysis for PROGRESS-AD trial planned for 1H 2026

Result Drivers

ABC PLATFORM - Alector's focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon Rosenthal

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$3.26 mln	$3.02 mln (6 Analysts)
Q3 EPS		-$0.34
Q3 Net Income		-$34.67 mln
Q3 Basic EPS		-$0.34

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Alector Inc is $1.50, about 16.3% above its November 5 closing price of $1.26

Press Release: ID:nGNX3cm25w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581049046"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581049046\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581049046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581049046","market":"nz","top_or_hot":-1,"title":"Clinical biotech firm Alector Q3 revenue beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Clinical biotech firm Alector Q3 revenue beats expectations </title></head><body><p><span>Overview</span></p><ul><li><p>Alector Q3 2025 revenue beats analyst expectations despite a year-over-year decline</p></li><li><p>Net loss for Q3 2025 narrows compared to the same period last year</p></li><li><p>Company implements 47% workforce reduction to focus on high-priority programs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates collaboration revenue between $13 mln and $18 mln for 2025</p></li><li><p>Alector targets IND filing for AL137 in 2026</p></li><li><p>Independent interim analysis for PROGRESS-AD trial planned for 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ABC PLATFORM - Alector's focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon Rosenthal</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.26 mln</p></td><td><p>$3.02 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.34</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$34.67 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.34</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 6 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Alector Inc is $1.50, about 16.3% above its November 5 closing price of $1.26</p></li></ul><p>Press Release: <span>ID:nGNX3cm25w</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical biotech firm Alector Q3 revenue beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical biotech firm Alector Q3 revenue beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 06:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Clinical biotech firm Alector Q3 revenue beats expectations </title></head><body><p><span>Overview</span></p><ul><li><p>Alector Q3 2025 revenue beats analyst expectations despite a year-over-year decline</p></li><li><p>Net loss for Q3 2025 narrows compared to the same period last year</p></li><li><p>Company implements 47% workforce reduction to focus on high-priority programs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates collaboration revenue between $13 mln and $18 mln for 2025</p></li><li><p>Alector targets IND filing for AL137 in 2026</p></li><li><p>Independent interim analysis for PROGRESS-AD trial planned for 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ABC PLATFORM - Alector's focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon Rosenthal</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.26 mln</p></td><td><p>$3.02 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.34</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$34.67 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.34</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 6 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Alector Inc is $1.50, about 16.3% above its November 5 closing price of $1.26</p></li></ul><p>Press Release: <span>ID:nGNX3cm25w</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1L9:1","article_id":"2581049046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581049046","pubTimestamp":1762467350,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clinical biotech firm Alector Q3 revenue beats expectationsOverviewAlector Q3 2025 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 2025 narrows compared to the same ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALEC":"Alector Inc."},"translate_title":"临床生物技术公司Alector第三季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALEC":0.9},"content_text":"Clinical biotech firm Alector Q3 revenue beats expectations OverviewAlector Q3 2025 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 2025 narrows compared to the same period last yearCompany implements 47% workforce reduction to focus on high-priority programsOutlookCompany anticipates collaboration revenue between $13 mln and $18 mln for 2025Alector targets IND filing for AL137 in 2026Independent interim analysis for PROGRESS-AD trial planned for 1H 2026Result DriversABC PLATFORM - Alector's focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon RosenthalKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$3.26 mln$3.02 mln (6 Analysts)Q3 EPS-$0.34Q3 Net Income-$34.67 mlnQ3 Basic EPS-$0.34Analyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 6 \"hold\" and 2 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Alector Inc is $1.50, about 16.3% above its November 5 closing price of $1.26Press Release: ID:nGNX3cm25wFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}